Incannex Healthcare Inc. Stock-Based Compensation
Incannex Healthcare Inc. (IXHL) reported Stock-Based Compensation of $6.37 million for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-05-15
- Incannex Healthcare Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.47M, a 252.28% increase year-over-year.
- Incannex Healthcare Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.28M, a 423.91% increase year-over-year.
- Incannex Healthcare Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.63M, a 472.11% increase year-over-year.
- Incannex Healthcare Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $1.30M, a 61.17% decline year-over-year.
- Incannex Healthcare Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $2.61M, a 70.78% decline from fiscal 2024.
- Incannex Healthcare Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $8.93M, a 315.45% increase from fiscal 2023.
- Incannex Healthcare Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.15M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $3.75M derived: sum of 2 quarters · filed 2026-05-15 | $6.37M 10-Q · filed 2026-05-15 | $7.67M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-13 | $4.91M 10-Q · filed 2026-02-13 | $6.20M derived: sum of 3 quarters · filed 2026-02-13 | $6.62M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-09-30 | $2.63M 10-Q · filed 2025-11-14 | $3.92M derived: sum of 2 quarters · filed 2025-11-14 | $4.34M derived: sum of 3 quarters · filed 2026-05-15 | $4.78M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-06-30 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $1.72M derived: sum of 2 quarters · filed 2026-05-15 | $2.15M derived: sum of 3 quarters · filed 2026-05-15 | $2.61M 10-K · filed 2025-09-29 |
| 2025-03-31 | $417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $852.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.31M 10-Q · filed 2026-05-15 | $4.65M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-13 | $894.00K 10-Q · filed 2026-02-13 | $4.24M derived: sum of 3 quarters · filed 2026-02-13 | $6.35M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $459.00K 10-Q · filed 2025-11-14 | $3.80M derived: sum of 2 quarters · filed 2025-11-14 | $5.92M derived: sum of 3 quarters · filed 2025-11-14 | $9.19M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $5.46M derived: sum of 2 quarters · filed 2025-09-29 | $8.73M derived: sum of 3 quarters · filed 2025-09-29 | $8.93M 10-K · filed 2025-09-29 |
| 2024-03-31 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-15 | $5.38M derived: sum of 2 quarters · filed 2025-05-15 | $5.58M 10-Q · filed 2025-05-15 | $6.10M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $3.47M 10-Q · filed 2025-02-14 | $3.99M derived: sum of 3 quarters · filed 2025-02-14 | $4.52M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $201.00K 10-Q · filed 2024-11-14 | $719.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.25M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $518.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $1.05M derived: sum of 2 quarters · filed 2024-09-30 | $2.15M 10-K · filed 2024-09-30 | |
| 2023-03-31 | $531.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $1.63M 10-Q · filed 2024-05-15 | ||
| 2022-12-31 | $1.10M 10-Q · filed 2024-02-14 | |||
| 2022-06-30 | $1.46M 20-F · filed 2022-10-28 | |||
| 2021-06-30 | $600.04K 20-F · filed 2022-10-28 | |||
| 2020-06-30 | $565.45K 20-F · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |